A5263
Current StudyA Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The National Canc …
ACTG
More about this study »A5300B
Current StudyProtecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx). Protocol summary: This trial is of household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which …
ACTG
More about this study »A5332 REPRIEVE Trial
Current StudyProtocol summary: In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in peo …
ACTG
More about this study »A5354
Current StudyThis study evaluates whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus. The study includes people w …
ACTG
More about this study »A5372
Current StudyDrug-Drug Interactions Between Rifapentine and Dolutegravir In HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study). Study summary The purpose of this research study is to see if taking medications to prevent tuberculosis (TB) affect the drug levels in …
ACTG
More about this study »A5379
Current StudyB-Enhancement of HBV Vaccination in Persons Living with HIV (BEe-HIVe): Evaluation Of HEPLISAV-B Study summary A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral infection that affects the live …
ACTG
More about this study »A5381
Current StudyObservational Cohort to Assess Therapeutic Efficacy And Emergence Of HIV Drug Resistance Following Initiation Of Tenofovir-Lamivudine-Dolutegravir (TLD) For First- Or Second-Line ART Protocol summary This is a study for people who have HIV and qualify …
ACTG
More about this study »A5349
Current StudyRifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. Protocol summary: The purpose of this study is to determine whether one or two four-month regimens of tubercul …
ACTG
More about this study »A5175
Completed StudyA Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily PI & Once-Daily Non-NRTI – Containing Therapy Combinations for Initial Treatment of HIV-1 Infected individuals from Resource – Limited Settings (PEARLS) Trial …
ACTG
More about this study »A5199
Completed StudyInternational Neuropsychological Assessment of Patients Initiating Antiretroviral Therapy in Resource-Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) US National Institute of Mental Health Summary: A5199 was …
ACTG
More about this study »A5185s
Completed StudyA Substudy of A5175: Effect of Initial Antiretroviral Treatment on Genital Compartment Virus in Individuals from Diverse Areas of the World Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5185s was a substud …
ACTG
More about this study »A5264
Completed StudyA Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy Versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource Limited Settings Sponsors: US National Institut …
ACTG
More about this study »A5190/P1054
Completed StudyAssessment of Safety and Toxicity among Infants Born To HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5190- …
ACTG
More about this study »A5199
Completed StudyInternational Neuropsychological Assessment of Patients Initiating Antiretroviral Therapy in Resource-Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) US National Institute of Mental Health Summary: A5199 was …
ACTG
More about this study »A5208
Completed StudyOptimal Combination Therapy After Nevirapine Exposure (OCTANE) Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5208 was a phase III study that comprised of two randomized clinical trials that were conducted …
ACTG
More about this study »A5221
Completed StudyA Strategy Study of Immediate Versus Deferred initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protoc …
ACTG
More about this study »A5225
Completed StudyA Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5225 was a phase I/II dose escalation and validat …
ACTG
More about this study »A5234
Completed StudyInternational Trial of Modified Directly Observed Therapy versus Self-Administered Therapy for Participants with First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen Sponsor: US National Institut …
ACTG
More about this study »A5265
Completed StudyA Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of OC in HIV-1 Infected Participants in Non-US Settings Sponsors: …
ACTG
More about this study »A5273
Completed StudyMulitcenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT) Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5273 is a phase III, dual-arm, open-label, randomized, non-inferiority stu …
ACTG
More about this study »A5274
Completed StudyReducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5274 is a randomized, open-label, phase IV strategy trial, where parti …
ACTG
More about this study »A5278
Completed StudyPharmacology Substudies of A5263 and A5264 Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The National Cancer Institute (NCI) National Institute on Dental Craniofacial Research (NIDCR) Protocol Summary: A5278 is designed to …
ACTG
More about this study »A5282
Completed StudyA Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-based Strategy for Prevention of CIN 2+ in HIV-infected Women Sponsor: US National institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5282 is a ra …
ACTG
More about this study »
